Last year, FDAacting through the Office of Prescription Drug Promotion (OPDP) within the Center for Drug Evaluation and Research (CDER)issued a high volume of untitled and warning letters as part of a broader push against directtoconsumer (DTC) drug advertising, including 58 letters addressing claims about compounded GLP1s (e.g., semaglutide and tirzepatide) and other compounded products (e.g., sildenafil and tadalafil).[2] By mid2026, activity appeared to taper offraising the question whether FDA had shifted priorities, for example due to personnel changes, or simply paused the effort
Step 4 Ongoing Support Your clinician guides and adjusts your therapy as needed
Key Improvements Over GHK-CU When to Choose SRCP Over GHK-CU SRCP formulations excel in specific situations where first-generation copper peptides fall short
2016) ototoxicity has been confirmed
LT: You look fantastic, as always
Debris was not included in the analysis